Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA

Дата публикации: 28-04-2026 19:04:20

London, UK -- 28 April 2026 GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted for priority review a New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO)...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
2	New Drug Application for Bayer’s FXIa Inhibitor Asundexian Accepted by U.S. Food and Drug Administration Under Priority Review	0	7.56	19-05-2026
3	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST	0	10.76	28-05-2026
4	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
5	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
6	U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma	0	6.44	13-07-2026
7	U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	0	11.68	28-04-2026
8	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026
9	Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer	0	14.56	22-07-2026
10	Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer	0	9.33	03-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.85. Источник: www.drugs.com.